Positive Linear Relationship between Nucleophosmin Protein Expression and the Viral Load in HPV-Associated Oropharyngeal Squamous Cell Carcinoma: A Possible Tool for Stratification of Patients.
Humans
Carcinoma, Squamous Cell
/ pathology
Cyclin-Dependent Kinase Inhibitor p16
DNA, Viral
/ genetics
Head and Neck Neoplasms
Human Papillomavirus Viruses
Nucleophosmin
Oncogene Proteins, Viral
/ genetics
Oropharyngeal Neoplasms
/ pathology
Papillomaviridae
/ genetics
Papillomavirus Infections
Retrospective Studies
Squamous Cell Carcinoma of Head and Neck
Viral Load
HPV
inflammation
nucleophosmin
oropharyngeal squamous cell carcinoma
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
09 Feb 2023
09 Feb 2023
Historique:
received:
12
01
2023
revised:
02
02
2023
accepted:
06
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
3
3
2023
Statut:
epublish
Résumé
Most oropharyngeal squamous cell carcinomas (OPSCCs) are human papillomavirus (HPV)-associated, high-risk (HR) cancers that show a better response to chemoradiotherapy and are associated with improved survival. Nucleophosmin (NPM, also called NPM1/B23) is a nucleolar phosphoprotein that plays different roles within the cell, such as ribosomal synthesis, cell cycle regulation, DNA damage repair and centrosome duplication. NPM is also known as an activator of inflammatory pathways. An increase in NPM expression has been observed in vitro in E6/E7 overexpressing cells and is involved in HPV assembly. In this retrospective study, we investigated the relationship between the immunohistochemical (IHC) expression of NPM and HR-HPV viral load, assayed by RNAScope in situ hybridization (ISH), in ten patients with histologically confirmed p16-positive OPSCC. Our findings show that there is a positive correlation between NPM expression and HR-HPV mRNA (Rs = 0.70,
Identifiants
pubmed: 36834892
pii: ijms24043482
doi: 10.3390/ijms24043482
pmc: PMC9967283
pii:
doi:
Substances chimiques
Cyclin-Dependent Kinase Inhibitor p16
0
DNA, Viral
0
Nucleophosmin
117896-08-9
Oncogene Proteins, Viral
0
NPM1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministero della Salute
ID : RF-02362708
Organisme : Ministero della Salute
ID : SG-12358253
Organisme : Ministero della Salute
ID : RC-2022
Organisme : Lega Italiana per la Lotta ai Tumori
ID : LILT-2022
Références
Papillomavirus Res. 2015 Dec;1:74-89
pubmed: 27398412
J Oral Pathol Med. 2019 Oct;48(9):773-779
pubmed: 30908732
J Oral Pathol Med. 2017 Aug;46(7):475-479
pubmed: 27864904
Asian Pac J Cancer Prev. 2019 Jul 01;20(7):2139-2143
pubmed: 31350977
BMC Cancer. 2009 May 13;9:146
pubmed: 19439079
BMC Mol Biol. 2016 Aug 24;17(1):19
pubmed: 27553022
PLoS One. 2014 May 05;9(5):e96136
pubmed: 24798431
Cell. 1990 Dec 21;63(6):1129-36
pubmed: 2175676
Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75
pubmed: 15734974
Cells. 2021 Jun 25;10(7):
pubmed: 34202380
J Oral Pathol Med. 2020 Feb;49(2):110-116
pubmed: 31465605
CA Cancer J Clin. 2017 Mar;67(2):122-137
pubmed: 28128848
J Natl Cancer Inst. 2009 Mar 18;101(6):412-23
pubmed: 19276448
Biotech Histochem. 2012 May;87(4):257-64
pubmed: 22149264
Front Cardiovasc Med. 2022 Apr 28;9:867813
pubmed: 35571214
Oral Oncol. 2016 Nov;62:101-108
pubmed: 27865361
Arch Pathol Lab Med. 2018 May;142(5):559-597
pubmed: 29251996
Mod Pathol. 2012 Sep;25(9):1212-20
pubmed: 22596101
J Clin Oncol. 2011 Nov 10;29(32):4294-301
pubmed: 21969503
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Int J Cancer. 2017 Aug 15;141(4):664-670
pubmed: 28369882
J Natl Cancer Inst. 2007 May 16;99(10):777-89
pubmed: 17505073
Mol Carcinog. 2017 May;56(5):1484-1492
pubmed: 27996172
BMC Biol. 2021 Jun 16;19(1):124
pubmed: 34134693
Am J Surg Pathol. 2011 Sep;35(9):1343-50
pubmed: 21836494
Lancet Oncol. 2010 Aug;11(8):781-9
pubmed: 20451455
Ann Oncol. 2013 Nov;24(11):2740-5
pubmed: 23946330
Sex Transm Dis. 2002 Mar;29(3):182-7
pubmed: 11875380
Oncogene. 1997 Mar 13;14(10):1137-45
pubmed: 9121762
Br J Cancer. 2013 Apr 2;108(6):1332-9
pubmed: 23412100
J Natl Cancer Inst. 2008 Feb 20;100(4):261-9
pubmed: 18270337
Cancer Med. 2015 Apr;4(4):596-607
pubmed: 25644715
Salud Publica Mex. 2009 Mar-Apr;51(2):134-40
pubmed: 19377740
Cancer. 2007 Oct 1;110(7):1429-35
pubmed: 17724670
J Virol. 2010 May;84(10):5131-9
pubmed: 20237089
Viruses. 2022 Jul 30;14(8):
pubmed: 36016303
Sci Rep. 2017 Dec 1;7(1):16715
pubmed: 29196639
Future Virol. 2011 Jan 1;6(1):45-57
pubmed: 21318095
Cancer Detect Prev. 2006;30(6):481-90
pubmed: 17113241
J Clin Pathol. 2020 Oct;73(10):624-629
pubmed: 32499224
Oral Oncol. 1997 Jul;33(4):247-59
pubmed: 9307714
Eur J Cancer B Oral Oncol. 1995 May;31B(3):174-80
pubmed: 7549757
J Mol Diagn. 2012 Jan;14(1):22-9
pubmed: 22166544
PLoS One. 2015 Dec 01;10(12):e0143634
pubmed: 26624888
J Exp Med. 2002 Oct 21;196(8):1067-78
pubmed: 12391018
Pathol Res Pract. 1992 Oct;188(7):866-73
pubmed: 1280356
Histopathology. 2012 May;60(6):982-91
pubmed: 22360821
Infect Disord Drug Targets. 2019;19(1):2-16
pubmed: 29589547
Oral Oncol. 2008 Feb;44(2):133-42
pubmed: 17360226
Lancet Oncol. 2014 Nov;15(12):1319-31
pubmed: 25439690